ZYNE - Zynerba Pharmaceuticals, Inc. Stock Price and Quote

ZYNE [NASD]

Healthcare | Drug Manufacturers - Specialty & Generic | USA

Index	-	P/E	-	EPS (ttm)	-0.87	Insider Own	2.70%	Shs Outstand	47.06M	Perf Week	-13.11%
Market Cap	20.90M	Forward P/E	-	EPS next Y	-0.67	Insider Trans	-6.52%	Shs Float	44.05M	Perf Month	-11.60%
Income	-35.80M	PEG	-	EPS next Q	-0.18	Inst Own	23.70%	Short Float / Ratio	0.54% / 0.73	Perf Quarter	-18.32%
Sales	-	P/S	-	EPS this Y	50.00%	Inst Trans	-0.89%	Short Interest	0.24M	Perf Half Y	-51.98%
Book/sh	1.21	P/B	0.35	EPS next Y	18.30%	ROA	-50.30%	Target Price	5.44	Perf Year	-80.17%
Cash/sh	1.12	P/C	0.37	EPS next 5Y	-	ROE	-58.20%	52W Range	0.39 - 2.28	Perf YTD	-22.94%
Dividend	-	P/FCF	-	EPS past 5Y	18.10%	ROI	-	52W High	-82.09%	Beta	1.74
Dividend %	-	Quick Ratio	6.40	Sales past 5Y	-	Gross Margin	-	52W Low	4.72%	ATR	0.04
Employees	28	Current Ratio	6.40	Sales Q/Q	-	Oper. Margin	-	RSI (14)	39.31	Volatility	12.66% 9.89%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	24.90%	Profit Margin	-	Rel Volume	0.34	Prev Close	0.42
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	325.73K	Price	0.41
Recom	1.70	SMA20	-8.11%	SMA50	-22.64%	SMA200	-48.90%	Volume	46,639	Change	-2.76%

Dec-21-20

Reiterated

H.C. Wainwright

Buy

$12 → $9

Jul-01-20

Downgrade

Needham

Buy → Hold

Dec-31-19

Resumed

ROTH Capital

Buy

$12

Oct-21-19

Initiated

Needham

Buy

$18

Apr-22-19

Resumed

Canaccord Genuity

Buy

Feb-01-18

Resumed

H.C. Wainwright

Buy

$23

Jan-29-18

Initiated

Ladenburg Thalmann

Buy

$25.50

Jan-26-18

Initiated

Seaport Global Securities

Buy

$16

Oct-02-17

Upgrade

Cantor Fitzgerald

Neutral → Overweight

$4 → $17

Sep-29-17

Upgrade

Piper Jaffray

Neutral → Overweight

Show Previous Ratings

Mar-28-23 07:30AM	Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights GlobeNewswire
Mar-13-23 04:15PM	Zynerba Pharmaceuticals Confirms Not Holding Cash Deposits or Securities at Silicon Valley Bank GlobeNewswire
Mar-07-23 07:00AM	Zynerba Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference GlobeNewswire
Mar-01-23 07:00AM	Zynerba Pharmaceuticals to Present at the Cowen 43rd Annual Health Care Conference GlobeNewswire
Jan-11-23 08:30AM	Zynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X Syndrome GlobeNewswire
09:56AM	Loading…
Jan-08-23 09:56AM	Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth? Simply Wall St.
Dec-21-22 07:29AM	UPDATE 2-Zynerba delays genetic disorder drug data on enrollment challenge Reuters
07:00AM	Zynerba Pharmaceuticals Announces Update on RECONNECT, the Pivotal Phase 3 Trial of Zygel in Fragile X Syndrome GlobeNewswire
Dec-05-22 07:30AM	Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the Annual Meeting of the American College of Neuropsychopharmacology GlobeNewswire
Nov-29-22 07:00AM	Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of Neuropsychopharmacology GlobeNewswire -5.28%
Nov-28-22 07:30AM	Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel in the Journal of Neurodevelopmental Disorders GlobeNewswire +6.44%
Nov-15-22 07:30AM	Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel in 22q11.2 Deletion Syndrome GlobeNewswire
Nov-14-22 07:30AM	Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights GlobeNewswire
Nov-02-22 07:30AM	Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel for the Treatment of 22q11.2 Deletion Syndrome GlobeNewswire
Oct-17-22 07:00AM	Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit GlobeNewswire
07:00AM	Loading…
Oct-10-22 07:00AM	Zynerba Pharmaceuticals Announces Poster Presentation at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit GlobeNewswire -5.57%
Oct-06-22 07:00AM	Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel GlobeNewswire +13.01%
Sep-29-22 07:00AM	Zynerba Pharmaceuticals to Participate in the Cantor Neurology & Psychiatry Conference GlobeNewswire -9.10%
Sep-22-22 07:00AM	Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Healthcare Conference GlobeNewswire
Sep-08-22 09:15AM	Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium GlobeNewswire +5.36%
Sep-06-22 07:00AM	Zynerba Pharmaceuticals to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference GlobeNewswire
Aug-31-22 07:00AM	Zynerba Pharmaceuticals Announces Oral Presentation at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium GlobeNewswire
Aug-10-22 07:00AM	Zynerba Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights GlobeNewswire
Aug-03-22 07:00AM	Zynerba Pharmaceuticals to Present In Person at the Canaccord Genuity 42nd Annual Growth Conference GlobeNewswire
Aug-01-22 07:11AM	We're Hopeful That Zynerba Pharmaceuticals (NASDAQ:ZYNE) Will Use Its Cash Wisely Simply Wall St.
Jul-21-22 07:00AM	Zynerba Pharmaceuticals Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital GlobeNewswire +9.57%
Jul-07-22 07:00AM	Zynerba Pharmaceuticals Announces Panel Presentation and Poster Presentations at the NFXF International Fragile X Conference GlobeNewswire
Jun-24-22 01:19PM	Lab Notes: AmerisourceBergen aims to help cell and gene therapy developers, Penn spinout expands research deal with university American City Business Journals
Jun-22-22 10:39AM	Zynerba's Cannabidiol Formulated Gel Shows Encouraging Action In Genetic Disease Benzinga
Jun-21-22 08:05PM	Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel in 22q11.2 Deletion Syndrome GlobeNewswire
07:00AM	Loading…
Jun-01-22 07:00AM	Zynerba Pharmaceuticals Presents Data on Zygel at the American Society of Clinical Psychopharmacology Annual Meeting GlobeNewswire -5.48%
May-24-22 07:00AM	Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the American Society of Clinical Psychopharmacology Annual Meeting GlobeNewswire -7.83%
May-17-22 07:00AM	Zynerba Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference GlobeNewswire +6.80%
May-16-22 07:00AM	Zynerba Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights GlobeNewswire +8.68%
May-11-22 01:30PM	Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel in Children and Adolescents with Fragile X Syndrome (FXS) at the International Society for Autism Research Annual Meeting GlobeNewswire -12.83%
May-09-22 04:57PM	Zynerba Pharmaceuticals Announces Podium Presentation at the International Society for Autism Research Annual Meeting GlobeNewswire -8.80%
May-02-22 07:00AM	Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel in Children and Adolescents with Fragile X Syndrome (FXS) at the 2022 Society of Biological Psychiatry Annual Meeting GlobeNewswire
Apr-21-22 07:00AM	Zynerba Pharmaceuticals Announces Presentation of Poster at the 2022 Society of Biological Psychiatry Annual Meeting GlobeNewswire
Apr-05-22 07:00AM	Zynerba Pharmaceuticals to Present at the Needham Virtual Healthcare Conference GlobeNewswire -5.34%
Mar-22-22 07:00AM	Zynerba Pharmaceuticals to Participate in the Cantor Rare Orphan Disease Summit GlobeNewswire +6.15%
Mar-08-22 10:00AM	Zynerba (ZYNE) Loses 29.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner Zacks
Mar-04-22 02:34PM	Lab notes: Myonex acquires German drug business; Vallon receives Covid drug treatment patent American City Business Journals
Mar-01-22 06:00AM	Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights GlobeNewswire
Feb-28-22 04:05PM	Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel in Fragile X Syndrome GlobeNewswire
07:00AM	Zynerba Pharmaceuticals Announces Completion of Enrollment in Phase 2 Trial of Zygel in 22q11.2 Deletion Syndrome GlobeNewswire
Feb-22-22 05:13AM	Companies Like Zynerba Pharmaceuticals (NASDAQ:ZYNE) Are In A Position To Invest In Growth Simply Wall St. -5.24%
Feb-15-22 07:00AM	Zynerba Pharmaceuticals Announces Planned Retirement of Suzanne Hanlon and Appoints Albert P. Parker as Chief Legal Officer GlobeNewswire
Feb-10-22 07:00AM	Zynerba Pharmaceuticals to Present at the SVB Leerink Global Healthcare Conference GlobeNewswire
Jan-06-22 07:00AM	Zynerba Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference GlobeNewswire
Jan-05-22 06:29AM	Zynerba Discontinues Development Of Cannabidiol Gel In Epileptic Disorders Benzinga -9.15%
Jan-04-22 04:05PM	Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE GlobeNewswire
Dec-06-21 07:00AM	Zynerba Pharmaceuticals Announces Presentation at The BRAIN Foundation Synchrony 2021 Symposium GlobeNewswire
Nov-22-21 07:00AM	Zynerba Pharmaceuticals Announces Issuance of New Patent in EU for Zygel GlobeNewswire
Nov-15-21 07:00AM	Zynerba Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Highlights GlobeNewswire
Oct-21-21 07:00AM	Zynerba Pharmaceuticals Announces Presentations at Two Upcoming Scientific Conferences in October GlobeNewswire
Oct-19-21 04:15PM	Zynerba Pharmaceuticals Announces Presentation of Poster at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit GlobeNewswire
Oct-08-21 07:30AM	Zynerba Pharmaceuticals Announces Presentation of Poster at the 2021 American Academy of Pediatrics National Conference & Exhibition GlobeNewswire
Sep-20-21 07:00AM	Zynerba Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference GlobeNewswire
Sep-13-21 07:00AM	Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel in Fragile X Syndrome GlobeNewswire
Sep-09-21 11:06AM	Zynerba Stock Moves Higher On Long-Term Zygel Data In Autistic Children Benzinga +5.32%
07:00AM	Zynerba Pharmaceuticals Presents Longer Term Tolerability and Efficacy Data of Zygel in Children and Adolescents with Autism Spectrum Disorder (ASD) at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021 GlobeNewswire
Sep-07-21 07:00AM	Zynerba Pharmaceuticals Announces Publication of Results of Phase 2 BELIEVE Open-Label Study of Zygel in Children and Adolescents with Developmental and Epileptic Encephalopathies (DEE) in JAMA Network Open GlobeNewswire
Sep-02-21 07:30AM	Zynerba Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference GlobeNewswire +6.34%
07:00AM	Zynerba Pharmaceuticals Announces Oral Presentations at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021 GlobeNewswire
Aug-09-21 07:00AM	Zynerba Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Highlights GlobeNewswire
Aug-04-21 07:30AM	Zynerba Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference GlobeNewswire
Aug-02-21 01:31PM	10 Best CBD Stocks to Invest In Insider Monkey
Jul-07-21 07:30AM	Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Virtual Healthcare Conference GlobeNewswire
Jun-30-21 07:00AM	Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting GlobeNewswire
Jun-29-21 09:01AM	Should I Buy Zynerba Pharmaceuticals Inc (ZYNE)? Insider Monkey
Jun-11-21 02:44PM	Zynerba's Zygel Improves Sleep In Children With Severe Epilepsies Benzinga
12:30PM	Zynerba Pharmaceuticals Presents Sleep Data from Study of Zygel in Children and Adolescents with Both Developmental and Epileptic Encephalopathies (DEE) and Autism Spectrum Disorder (ASD) at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting GlobeNewswire
Jun-09-21 04:05PM	Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting GlobeNewswire
Jun-07-21 08:00AM	Pomerantz LLP and The Rosen Law Firm, P.A. Announce Proposed Class Action Settlement on Behalf of Purchasers of Securities of Zynerba Pharmaceuticals, Inc. ZYNE GlobeNewswire
Jun-04-21 07:30AM	Zynerba Pharmaceuticals Announces Acceptance of Poster at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting GlobeNewswire
Jun-03-21 10:00AM	Zynerba Pharmaceuticals Announces Presentation of Efficacy and Safety Findings in Children and Adolescents with Autism Spectrum Disorder (ASD) and Related Disorders at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting GlobeNewswire
May-27-21 07:30AM	Zynerba Pharmaceuticals Announces Acceptance of Poster at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting GlobeNewswire
May-26-21 07:30AM	Zynerba Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference GlobeNewswire +5.45%
07:00AM	Notice of Settlement of Derivative Actions GlobeNewswire
May-17-21 08:00AM	Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the International Society for Pharmacoeconomic and Outcomes Research (ISPOR) Virtual 2021 Conference GlobeNewswire
May-12-21 06:45AM	Zynerba Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Highlights GlobeNewswire
May-06-21 07:53AM	Zynerba Pharma Receives FDA Guidance For Phase 3 Trial Of Zygel; Street Sees 75% Upside SmarterAnalyst -8.03%
May-05-21 04:05PM	Zynerba Pharmaceuticals Announces Phase 3 RECONNECT Trial Design for Zygel in Fragile X Syndrome GlobeNewswire
Apr-29-21 02:00PM	Zynerba Pharmaceuticals Presents Two Posters at the Society of Biological Psychiatry 2021 Virtual Meeting GlobeNewswire
Apr-15-21 07:30AM	Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the Society of Biological Psychiatry 2021 Virtual Meeting GlobeNewswire -6.93%
Apr-06-21 07:30AM	Zynerba Pharmaceuticals to Present at the Needham Virtual Healthcare Conference GlobeNewswire
Mar-31-21 12:15PM	Inside the Top-Performing ETFs of Q1 Zacks
Mar-28-21 08:15AM	Zynerba (ZYNE) Alert: Shareholder Class Action Survives Motion to Dismiss; Should Management be Held Accountable for Investors Losses? Contact Johnson Fistel PR Newswire
Mar-12-21 05:22AM	Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth? Simply Wall St.
Mar-10-21 06:45AM	Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights GlobeNewswire
Mar-05-21 05:50PM	Zynerba Pharmaceuticals (ZYNE) Gains But Lags Market: What You Should Know Zacks
Mar-04-21 08:00AM	Zynerba Pharmaceuticals to Participate in the 33rd Annual ROTH Conference GlobeNewswire -9.31%
Feb-26-21 05:50PM	Zynerba Pharmaceuticals (ZYNE) Gains As Market Dips: What You Should Know Zacks
Feb-11-21 11:29AM	GW Deal With Jazz Spurs Pot Stock Wave, a Look at Smaller Players Market Exclusive -30.25%
Feb-03-21 04:25PM	GW Pharma Soars To Record High On Jazz's $7.2 Billion Takeover Deal Investor's Business Daily +27.39%
Jan-04-21 07:30AM	Zynerba Pharmaceuticals to Present at Two January Virtual Investor Conferences GlobeNewswire
Dec-23-20 05:30AM	Here's What We Think About Zynerba Pharmaceuticals' (NASDAQ:ZYNE) CEO Pay Simply Wall St.
Dec-17-20 08:10AM	The Daily Biotech Pulse: MacroGenics Breast Cancer Drug Wins FDA Approval, Adcom Test Awaits Moderna, Virios To Make Wall Street Debut Benzinga -16.51%
06:30AM	Zynerba Pharmaceuticals Provides Regulatory Update on Zygel in Fragile X Syndrome GlobeNewswire
Dec-09-20 03:49PM	Shuman, Glenn & Stecker Investigates Zynerba Pharmaceuticals, Inc. Business Wire

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Parker Albert P	Chief Legal Officer	Feb 15	Sale	0.54	3,173	1,719	227,018	Feb 17 04:21 PM
ANIDO ARMANDO	Chairman & Chief Exec. Officer	Jan 23	Sale	0.60	35,453	21,194	576,235	Jan 25 05:25 PM
Sebree Terri B	President	Jan 23	Sale	0.60	24,661	14,742	343,204	Jan 25 05:29 PM
Fickenscher James E	Chief Financial Officer	Jan 23	Sale	0.60	17,769	10,622	154,736	Jan 25 05:28 PM
Rosenberger Brian	VP, Commercial & Business Dev.	Jan 23	Sale	0.60	12,663	7,570	94,848	Jan 25 05:26 PM
ANIDO ARMANDO	Chairman & CEO	Jul 19	Sale	1.10	11,899	13,089	611,688	Jul 20 04:05 PM
Sebree Terri B	President	Jul 19	Sale	1.10	8,281	9,109	367,865	Jul 20 04:08 PM
Fickenscher James E	Chief Financial Officer	Jul 19	Sale	1.10	6,013	6,614	172,505	Jul 20 04:05 PM
Rosenberger Brian	VP, Commercial & Business Dev.	Jul 19	Sale	1.10	4,289	4,718	107,511	Jul 20 04:06 PM
Butler John P.	Director	Jun 14	Sale	1.01	53	54	33,056	Jun 16 09:48 PM
KISNER DANIEL L	Director	Jun 14	Sale	1.01	40	40	28,069	Jun 16 09:53 PM
FEDERICI WILLIAM J	Director	Jun 14	Sale	1.01	40	40	28,069	Jun 16 09:52 PM
Stephenson Pamela	Director	Jun 14	Sale	1.01	40	40	28,069	Jun 16 09:51 PM
MOCH KENNETH I	Director	Jun 14	Sale	1.01	40	40	28,069	Jun 16 09:50 PM
COOPER WARREN D	Director	Jun 14	Sale	1.01	40	40	28,069	Jun 16 09:49 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience